Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease
暂无分享,去创建一个
Y. Amoako | C. Robinson | F. Sarfo | R. Phillips | M. Wansbrough-Jones | Y. Adu-Sarkodie | Jihui Zhang | Justice Abotsi | M. Abass
[1] O. Stojadinović,et al. Clinical application of growth factors and cytokines in wound healing , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[2] Y. Amoako,et al. Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease , 2014, Antimicrobial Agents and Chemotherapy.
[3] Marie-France Carlier,et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. , 2013, The Journal of clinical investigation.
[4] C. Robinson,et al. Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease , 2013, PLoS neglected tropical diseases.
[5] Y. Amoako,et al. Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay , 2012, PLoS neglected tropical diseases.
[6] Georges Bismuth,et al. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression , 2011, Proceedings of the National Academy of Sciences.
[7] Enrico Colombo,et al. A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells. , 2010, Microbes and infection.
[8] M. Ståhle,et al. Antioxidants Protect Keratinocytes against M. ulcerans Mycolactone Cytotoxicity , 2010, PloS one.
[9] F. Sarfo,et al. Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment of Mycobacterium ulcerans Disease , 2010, Antimicrobial Agents and Chemotherapy.
[10] G. Bretzel,et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial , 2010, The Lancet.
[11] F. Sarfo,et al. Detection of Mycolactone A/B in Mycobacterium ulcerans–Infected Human Tissue , 2010, PLoS neglected tropical diseases.
[12] B. Foxwell,et al. Mycolactone Inhibits Monocyte Cytokine Production by a Posttranscriptional Mechanism1 , 2009, The Journal of Immunology.
[13] F. Sarfo,et al. Sensitivity of PCR Targeting Mycobacterium ulcerans by Use of Fine-Needle Aspirates for Diagnosis of Buruli Ulcer , 2009, Journal of Clinical Microbiology.
[14] Olivera Stojadinovic,et al. PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[15] Hui Hong,et al. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria , 2008, Natural product reports.
[16] Angelo Martino,et al. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone , 2007, The Journal of experimental medicine.
[17] Sarojini Adusumilli,et al. Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with Mycobacterium ulcerans Has Implications for the Control of Infection , 2007, Infection and Immunity.
[18] Pierre Legras,et al. Impact of Mycobacterium ulcerans Biofilm on Transmissibility to Ecological Niches and Buruli Ulcer Pathogenesis , 2007, PLoS pathogens.
[19] Sarojini Adusumilli,et al. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo , 2005, Cellular microbiology.
[20] C. Horsfield,et al. Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans , 2005, Antimicrobial Agents and Chemotherapy.
[21] Emmanuelle Perret,et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin , 2005, Cellular microbiology.
[22] Sarojini Adusumilli,et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] K. Dobos,et al. Mycobacterium ulcerans Cytotoxicity in an Adipose Cell Model , 2001, Infection and Immunity.
[24] B. Foxwell,et al. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. , 1999, Journal of immunology.
[25] D. Chatterjee,et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. , 1999, Science.